Algene Holding SE Publishes Positive Interim Results From a Study With the Technical University of Munich (TUM), Positioning Itself Within the Growing Aquaculture Market

Algene reported statistically significant interim differences in shrimp feed consumption after only a few days, with higher consumption in the group receiving feed enriched with 100% Spirulina; the findings may indicate improved shrimp growth but remain preliminary. The TUM-collaborative study is scheduled to conclude in November, and confirmation would provide proof of concept as Algene pursues advanced discussions with potential aquaculture customers. The company cited projections for the global aquaculture market to grow from $653.8 billion in 2026 to $1.2 trillion by 2034, a 7.3% CAGR.

Analysis

The investable question is not whether shrimp consume the feed, but whether Spirulina improves saleable output per dollar of feed. Higher intake alone could raise input costs without improving feed-conversion ratio, growth, survival, or harvest timing; the release provides no commercial economics or independently verified customer commitments. TUM’s involvement adds scientific credibility, but should not be treated as endorsement of Algene’s product or a commercial validation.

The November readout is the near-term catalyst. Look for controlled results on weight gain, feed-conversion ratio, survival, sample size and duration, plus the inclusion rate and cost per kilogram of harvested shrimp. If efficacy is confirmed and scaled economics work, shrimp producers could benefit first; established aquafeed suppliers such as Skretting, Cargill Aqua Nutrition and BioMar could face substitution pressure only if customers adopt the ingredient at meaningful volumes. Any impact on fishmeal or other feed inputs is currently hypothetical.

The contrarian risk is that “higher consumption” is framed as an economic win even though it may simply mean more feed is needed. Even a positive proof of concept would leave formulation cost, production capacity, regulatory requirements and repeat orders unresolved. With no supplied ticker mapping and no disclosed revenue contribution, this is a catalyst watch rather than a fundamental long signal.

Key Decisions for Investors

• Do not chase the interim announcement. Reassess after the expected November results; require feed-conversion ratio and growth/survival data, not consumption alone.
• Treat Algene as a watch item pending verification of commercial scale: confirm inclusion rate, delivered cost, production capacity, regulatory status and whether customer discussions convert into paid pilots or orders.
• If final results show better saleable yield at a competitive feed cost, investigate Algene exposure and potential adoption by shrimp producers; the thesis is falsified if higher intake fails to improve feed conversion or harvest economics.
• Avoid positioning against incumbent aquafeed suppliers on this release alone. Revisit only if multiple customers disclose scaled adoption or competitors report measurable formulation displacement.